期刊档案 · Medicine-Ophthalmology
Ophthalmology Retina
ISSN 2468-6530 · Elsevier
Ophthalmology Retina 中科院 医学 2区（2025 年升级版），影响因子 5.9（官网公布），混合开放获取，APC 约 3,920 美元，近 24 个月 122 篇文章投稿到接收中位 49 天，2025 年发文 286 篇，ESCI、Scopus 收录。
研究范围
研究范围与定位
Ophthalmology Retina 由 Elsevier 出版，属中科院医学大类（2025 升级版2区）。按 OpenAlex 近年发文统计，该刊主要发表 Retinal Diseases and Treatments、Retinal and Macular Surgery、Retinal Imaging and Analysis 等主题的论文，这 3 个主题约占 36.4%，主导子领域为 Ophthalmology。（根据 OpenAlex 主题统计与中科院分区数据生成）
Ophthalmology Retina, a journal of the American Academy of Ophthalmology, serves society by publishing clinical and basic science research and other relevant manuscripts that relate to the sense of sight. Excellence is pursued through unbiased peer-review, the advancement of innovation and discovery, and the promotion of lifelong learning.Disclaimer Notice: Statements and opinions expressed in Ophthalmology Retina are those of the author(s) and are not necessarily those of the Academy or publisher, or indicative of Academy views, policy or editorial concurrence. The Editor(s), the Academy, and the Publisher assume no responsibility for any injury and/or damage to persons or property as a matter of product liability, negligence, or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein including those in a language other than English. No suggested test or procedure should be carried out unless, in the reader's judgment, its risk is justified and the patient has received information sufficient to give a fully informed consent. Because of the rapid advances in the medical sciences, medical practitioners should obtain independent verification of diagnoses and drug dosages. Discussions, views, and recommendations as to medical procedures, choice of drugs, and drug dosages are the responsibility of the authors. Consumers should consult with their own doctors about their individual health status before making any health decisions. The Academy does not endorse companies, drugs or other products.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：Medicine-Ophthalmology
主编 Andrew Schachat出版商官网
编委会国家分布：未见中国大陆编委；主要国家 美国 24、澳大利亚 3、荷兰 3、英国 2、新加坡 1（共 33 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Retinal Diseases and TreatmentsMedicine17.8%
- Retinal and Macular SurgeryMedicine11.3%
- Retinal Imaging and AnalysisMedicine7.3%
- Ocular Diseases and Behçet’s SyndromeMedicine7.3%
- Retinal and Optic ConditionsMedicine6.7%
- Ophthalmology and Visual Impairment StudiesMedicine5.8%
- Intraocular Surgery and LensesMedicine5.5%
- Glaucoma and retinal disordersMedicine4.6%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 眼科学OPHTHALMOLOGY | 1 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 1 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 1 区 |
| 小类 | 眼科学OPHTHALMOLOGY | 1 区 |
Top 期刊：是综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
数据库收录
ESCIScopusLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子（出版商公布）
- 5.9出版商官网 ·
- CiteScore 2026-06
- 9.1LetPub ·
- CiteScore（出版商公布）
- 9.1出版商官网 ·
- SJR 2026-06
- 2.1LetPub ·
- SNIP 2026-06
- 2.29LetPub ·
- h-index
- 69OpenAlex ·
- i10-index
- 806OpenAlex ·
- 两年平均被引
- 2.37OpenAlex ·
- 自引率
- 5.1%LetPub ·
- Gold OA 文章占比
- 32.49%LetPub ·
发文规模
- 年文章数
- 119LetPub ·
逐年发文量 OpenAlex 统计 · 累计 2,575 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 235 | 64 | 45 |
| 2025 | 286 | 73 | 534 |
| 2024 | 290 | 93 | 1,340 |
| 2023 | 267 | 74 | 2,311 |
| 2022 | 272 | 99 | 3,343 |
| 2021 | 194 | 48 | 2,540 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 PubMed 登记的稿件日期 · 至
49 天投稿到接收中位数 · P25–P75 20 天 – 97 天
- 接收到上线
- 中位数 11 天（120 篇）
- 投稿到上线
- 中位数 68 天
- 样本
- 122 篇有投稿与接收日期的文章（窗口内共 643 篇），最近一篇接收于
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 投稿到首次决定
- 4 天出版商官网 ·
- 外审后首次决定
- 37 天出版商官网 ·
- 投稿到接收
- 44 天出版商官网 ·
- 接收到发表
- 7 天出版商官网 ·
- 评审方式
- 单盲同行评审出版商官网
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
混合开放获取LetPub
订阅期刊，作者可付费选择开放获取发表。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| OpenAlex | USD 3,920 / EUR 3,670 / GBP 3,140 / JPY 486,200 | — | — | |
| 出版商官网 | USD 3,300 | — | — |
混合期刊的文章处理费仅在作者选择开放获取发表时收取；按订阅方式发表通常不收费。
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点3 项，摘自作者指南
- 摘要
- ≤ 350 词
- 参考文献格式
- AMA 格式
- 投稿信（Cover letter）
- 必须提供
接收的文章类型10 种，含篇幅限制
- aao meeting paperAAO Meeting Paper – A manuscript based on material that has or will be presented at an American Academy of Ophthalmology Annual Meeting.未说明篇幅
- correspondenceCorrespondence allows concise commentary about an article published in the journal within 6 months of its online posting. The text should raise a question for c…正文 ≤ 700 词 · 参考文献 ≤ 5
- editorialEditorials are usually solicited by the Editor-in-Chief. While unsolicited submissions are welcome, they are rarely considered. Editorials may address clinical …正文 ≤ 1,700 词
- manuscriptsManuscripts – A standard submission; a manuscript that does not fall into any of the following categories.未说明篇幅
- pictures & perspectivesPictures & Perspectives – Photographs, photomicrographs, radiologic or other imaging studies, or procedural illustrations that depict novel features of clinical…未说明篇幅
- report-invitedReport-Invited – Typically by invitation from the Editorial Board.未说明篇幅
- reviewIt is the corresponding author's responsibility to check periodically the status of his/her manuscript. An email with a decision will be sent with instructions …未说明篇幅
- systematic reviewSystematic reviews seek to collect, synthesize, and critically assess all evidence that fits pre-specified criteria to answer a clinical question pertaining to …未说明篇幅
- systematic review or meta-analysisSystematic Review or Meta-analysis – Please see specific criteria for submission in the Systematic Review/ Meta-analysis section in this Guide.未说明篇幅
- translational science reviewsTranslational Science Reviews – Typically by invitation from the Editorial Board.未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、数据可用性、出版伦理、许可与版权、开放获取、同行评审、查重、预印本、自存档、试验注册 / 报告规范
- AI 使用 Declaration of generative AI in scientific writing
Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incompl…
原文 ↗出版商官网 ·- 作者资格 Authorship
The journal adheres to the Uniform Requirements set by the International Committee of Medical Journal Editors (https://www.icmje.org/) for authorship. Each author must meet criteria for Authorship. The ICMJE recommends that authorship be based on the following 4 criteria:Substantial contributions to conception or design of the work; or the acquisition, analysis, or interpretation of data for the w…
原文 ↗出版商官网 ·- 利益冲突 Disclosure instructions
Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’. Statement: During the preparation of this work the…
原文 ↗出版商官网 ·- 数据可用性 Data sharing
To promote transparency and opportunities for further research, authors of work published in Ophthalmology Retina are encouraged to provide access to relevant datasets in compliance with contemporary reporting standards. Authors may use domain-specific public archives (for example, ClinicalTrials.gov, GenBank, Protein Data Bank), or generic databases (for example, Dataverse, Dryad, Mendeley, or th…
原文 ↗出版商官网 ·- 出版伦理 Publication ethics
Before completing the online submission, authors will have to confirm that their submission is in conformity with the Elsevier Guidelines for Ethics in Publishing, see https://www.elsevier.com/publishingethics and https://www.elsevier.com/ethicalguidelines.
原文 ↗出版商官网 ·- 许可与版权 Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see https://www.elsevier.com/copyright). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.Subscribers may reproduce …
原文 ↗出版商官网 ·- 开放获取 Green open access
Green open access embargo period of 12 months. 模型摘要
Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our open access page for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for public…
原文 ↗出版商官网 ·- 同行评审 Peer review
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor-in-Chief is responsible for the final decision regarding acceptance or rejection of articles. Th…
原文 ↗出版商官网 ·- 查重 Prior and repetitive publication; plagiarism
The journal will not consider manuscripts that have appeared in other journals, in part or in whole, in other publications, except in special circumstances approved by the Editor-in-Chief. Likewise, updates of previously published studies that add minimal new information to an existing publication will not be considered. Overlap between patient groups described in serial manuscripts must be acknow…
原文 ↗出版商官网 ·- 预印本 Preprint server
For work submitted to a preprint server, it is the corresponding author's responsibility to promptly update the preprint server entry to indicate when a paper has been accepted and is currently in press; the author must add proper citation of the online version to the preprint server entry to point users to the peer-reviewed, accepted version of the article.
原文 ↗出版商官网 ·- 自存档 Green open access
Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our open access page for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for public…
原文 ↗出版商官网 ·- 试验注册 / 报告规范 Clinical trials and clinical trial registration
A clinical trial is defined as any study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. With regards to the reporting of clinical trials, Ophthalmology Retina's policies are similar to the policies of The New England Journal of Medicine (NEJM), and The Journal of the American Medical Associat…
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Elsevier
- ISSN
- 2468-6530
- 印刷版 ISSN
- 2468-7219
- 官方链接
- 期刊主页 ↗LetPub
- 投稿系统 ↗出版商官网
- 专刊 / 特刊征稿 ↗出版商官网
常见问题
关于 Ophthalmology Retina 的常见问题
Ophthalmology Retina 是中科院几区期刊？
2025 年升级版分区表中，Ophthalmology Retina 为医学 2区，小类 眼科学 1 区。2026 年新锐版分区表中为医学 1区。不同版本与大小类分区不能混用。
Ophthalmology Retina 的影响因子是多少？
期刊官网公布的影响因子为 5.9，属期刊自述数据，LetPub 暂无该刊的影响因子记录，CiteScore 为 9.1，h-index 为 69。
Ophthalmology Retina 的审稿周期多长？
按 2024年10月至2026年10月（近 24 个月）122 篇已发表文章登记的日期，投稿到接收的中位数为 49 天（四分位 20–97 天）。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Ophthalmology Retina 的投稿格式要求是什么？
据期刊作者指南：摘要：≤ 350 词；参考文献格式：AMA 格式；投稿信：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Ophthalmology Retina 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 33 位编委中，没有中国大陆学者；人数最多的国家是 美国（24 位）、澳大利亚（3 位）、荷兰（3 位）。统计按编委会页面列出的机构国家计，仅供参考。
Ophthalmology Retina 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Ophthalmology Retina 被 ESCI、Scopus 收录。
Ophthalmology Retina 是开放获取期刊吗？版面费多少？
Ophthalmology Retina 为混合开放获取。选择开放获取发表时APC 约 3,920 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-26 归档）。最近更新：。